Concepts (243)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 32 | 2024 | 570 | 7.890 |
Why?
|
| Kidney Failure, Chronic | 13 | 2024 | 950 | 2.560 |
Why?
|
| Frailty | 4 | 2024 | 136 | 2.530 |
Why?
|
| Hyperoxaluria, Primary | 6 | 2021 | 12 | 1.670 |
Why?
|
| Living Donors | 6 | 2024 | 116 | 1.590 |
Why?
|
| Pyridoxine | 2 | 2020 | 15 | 1.110 |
Why?
|
| Altruism | 2 | 2024 | 25 | 0.910 |
Why?
|
| Graft Rejection | 7 | 2024 | 559 | 0.900 |
Why?
|
| Inflammation Mediators | 1 | 2024 | 240 | 0.810 |
Why?
|
| Nephrectomy | 1 | 2024 | 178 | 0.800 |
Why?
|
| Aftercare | 1 | 2024 | 155 | 0.800 |
Why?
|
| Cellular Senescence | 1 | 2024 | 199 | 0.790 |
Why?
|
| Kidney Diseases | 5 | 2021 | 489 | 0.780 |
Why?
|
| Self Report | 1 | 2024 | 549 | 0.700 |
Why?
|
| Self-Management | 1 | 2022 | 104 | 0.680 |
Why?
|
| Patient Readmission | 1 | 2024 | 425 | 0.670 |
Why?
|
| Vitamin B Complex | 1 | 2020 | 42 | 0.650 |
Why?
|
| Hyperoxaluria | 3 | 2021 | 6 | 0.630 |
Why?
|
| Biomarkers | 3 | 2024 | 3404 | 0.620 |
Why?
|
| Middle Aged | 27 | 2024 | 28943 | 0.610 |
Why?
|
| Paraproteinemias | 4 | 2021 | 22 | 0.600 |
Why?
|
| Waiting Lists | 2 | 2024 | 237 | 0.580 |
Why?
|
| Immunoglobulin Light Chains | 4 | 2020 | 24 | 0.560 |
Why?
|
| Risk Factors | 13 | 2024 | 10933 | 0.550 |
Why?
|
| Adult | 28 | 2024 | 31536 | 0.550 |
Why?
|
| Graft Survival | 6 | 2018 | 473 | 0.530 |
Why?
|
| Inflammation | 1 | 2024 | 1519 | 0.520 |
Why?
|
| Hypertension | 2 | 2024 | 1396 | 0.520 |
Why?
|
| Glomerular Filtration Rate | 6 | 2024 | 573 | 0.500 |
Why?
|
| Kidney | 6 | 2021 | 1330 | 0.480 |
Why?
|
| Kidney Function Tests | 4 | 2024 | 138 | 0.480 |
Why?
|
| Follow-Up Studies | 8 | 2024 | 5408 | 0.470 |
Why?
|
| Prognosis | 9 | 2024 | 5007 | 0.470 |
Why?
|
| Amyloidosis | 2 | 2020 | 73 | 0.450 |
Why?
|
| Health Status | 1 | 2017 | 407 | 0.450 |
Why?
|
| Exercise Therapy | 2 | 2022 | 182 | 0.440 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 2 | 2013 | 19 | 0.430 |
Why?
|
| Renal Dialysis | 3 | 2021 | 947 | 0.410 |
Why?
|
| Humans | 47 | 2024 | 131924 | 0.410 |
Why?
|
| Female | 31 | 2024 | 70584 | 0.400 |
Why?
|
| Postoperative Care | 1 | 2015 | 312 | 0.400 |
Why?
|
| Male | 30 | 2024 | 64870 | 0.390 |
Why?
|
| Arthritis | 1 | 2013 | 86 | 0.390 |
Why?
|
| Patient Compliance | 1 | 2015 | 473 | 0.370 |
Why?
|
| Prospective Studies | 5 | 2024 | 6569 | 0.360 |
Why?
|
| Risk Assessment | 4 | 2024 | 3732 | 0.360 |
Why?
|
| Potassium Channels | 4 | 1999 | 160 | 0.340 |
Why?
|
| Oxalates | 3 | 2020 | 22 | 0.340 |
Why?
|
| Kidney Calculi | 1 | 2011 | 49 | 0.330 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 3 | 1999 | 39 | 0.330 |
Why?
|
| Aged | 16 | 2024 | 21385 | 0.330 |
Why?
|
| Urography | 1 | 2010 | 32 | 0.320 |
Why?
|
| Multiple Myeloma | 2 | 2010 | 204 | 0.320 |
Why?
|
| Hypergammaglobulinemia | 1 | 2010 | 11 | 0.320 |
Why?
|
| Renal Insufficiency | 2 | 2010 | 256 | 0.320 |
Why?
|
| Renal Artery | 1 | 2010 | 69 | 0.310 |
Why?
|
| Incidental Findings | 1 | 2010 | 129 | 0.300 |
Why?
|
| Vascular Diseases | 1 | 2010 | 150 | 0.280 |
Why?
|
| Quality of Life | 2 | 2022 | 2157 | 0.280 |
Why?
|
| Postoperative Complications | 3 | 2024 | 3139 | 0.280 |
Why?
|
| Coronary Angiography | 1 | 2010 | 485 | 0.280 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2011 | 2166 | 0.270 |
Why?
|
| Calcium Oxalate | 3 | 2021 | 24 | 0.260 |
Why?
|
| Transplant Recipients | 3 | 2024 | 225 | 0.250 |
Why?
|
| Urinary Tract Infections | 1 | 2010 | 317 | 0.250 |
Why?
|
| Glomerulonephritis, Membranous | 2 | 2016 | 14 | 0.240 |
Why?
|
| Young Adult | 7 | 2022 | 9952 | 0.230 |
Why?
|
| Cardiovascular Diseases | 2 | 2015 | 2091 | 0.230 |
Why?
|
| Coronary Vessel Anomalies | 2 | 2007 | 290 | 0.230 |
Why?
|
| Treatment Outcome | 10 | 2024 | 12991 | 0.210 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2006 | 275 | 0.200 |
Why?
|
| Survival Analysis | 4 | 2019 | 1572 | 0.200 |
Why?
|
| West Nile Fever | 1 | 2005 | 139 | 0.200 |
Why?
|
| Allografts | 3 | 2024 | 195 | 0.200 |
Why?
|
| Myocardium | 3 | 2009 | 906 | 0.180 |
Why?
|
| Minnesota | 2 | 2019 | 180 | 0.180 |
Why?
|
| Retrospective Studies | 10 | 2024 | 17374 | 0.180 |
Why?
|
| Opportunistic Infections | 2 | 2013 | 79 | 0.180 |
Why?
|
| Fecal Incontinence | 1 | 2022 | 78 | 0.180 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2021 | 12 | 0.180 |
Why?
|
| Adenosine Triphosphate | 2 | 1999 | 275 | 0.170 |
Why?
|
| Predictive Value of Tests | 2 | 2024 | 2311 | 0.170 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 1 | 2020 | 12 | 0.170 |
Why?
|
| Pancreas Transplantation | 1 | 2020 | 31 | 0.170 |
Why?
|
| Transaminases | 1 | 2020 | 36 | 0.170 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2021 | 87 | 0.170 |
Why?
|
| Bariatric Surgery | 1 | 2022 | 139 | 0.160 |
Why?
|
| Diabetic Nephropathies | 1 | 2021 | 115 | 0.160 |
Why?
|
| Diabetes Mellitus | 2 | 2021 | 923 | 0.160 |
Why?
|
| Donor Selection | 1 | 2020 | 58 | 0.160 |
Why?
|
| Cost of Illness | 1 | 2021 | 284 | 0.160 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2008 | 1197 | 0.150 |
Why?
|
| Cohort Studies | 4 | 2022 | 5163 | 0.150 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 298 | 0.150 |
Why?
|
| Homozygote | 1 | 2020 | 547 | 0.140 |
Why?
|
| Lower Extremity | 1 | 2020 | 188 | 0.140 |
Why?
|
| Receptors, Drug | 1 | 1998 | 27 | 0.140 |
Why?
|
| Recovery of Function | 1 | 2020 | 461 | 0.140 |
Why?
|
| Isoantibodies | 1 | 2018 | 58 | 0.140 |
Why?
|
| Logistic Models | 2 | 2015 | 1839 | 0.140 |
Why?
|
| Electrocardiography | 1 | 2023 | 1000 | 0.130 |
Why?
|
| Polyomavirus Infections | 1 | 2018 | 90 | 0.130 |
Why?
|
| Tumor Virus Infections | 1 | 2018 | 139 | 0.130 |
Why?
|
| Preoperative Period | 1 | 2017 | 92 | 0.130 |
Why?
|
| Physical Fitness | 1 | 2017 | 91 | 0.130 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 1998 | 197 | 0.130 |
Why?
|
| Aged, 80 and over | 4 | 2022 | 7097 | 0.130 |
Why?
|
| Tissue Donors | 2 | 2018 | 504 | 0.120 |
Why?
|
| Disease Progression | 2 | 2015 | 2221 | 0.120 |
Why?
|
| Graft vs Host Disease | 1 | 2020 | 627 | 0.120 |
Why?
|
| Receptors, Phospholipase A2 | 1 | 2015 | 4 | 0.120 |
Why?
|
| Polyradiculoneuropathy | 1 | 2015 | 6 | 0.110 |
Why?
|
| Actigraphy | 1 | 2015 | 48 | 0.110 |
Why?
|
| Sural Nerve | 1 | 2015 | 46 | 0.110 |
Why?
|
| Sex Factors | 1 | 2019 | 1351 | 0.110 |
Why?
|
| Exercise | 1 | 2020 | 858 | 0.110 |
Why?
|
| Recurrence | 3 | 2016 | 1452 | 0.110 |
Why?
|
| Encephalitozoon cuniculi | 1 | 2013 | 1 | 0.100 |
Why?
|
| Encephalitozoonosis | 1 | 2013 | 1 | 0.100 |
Why?
|
| Complement C3 | 1 | 2013 | 51 | 0.100 |
Why?
|
| Biopsy | 3 | 2015 | 1284 | 0.100 |
Why?
|
| Synovial Fluid | 1 | 2013 | 17 | 0.100 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 3760 | 0.100 |
Why?
|
| Immunoglobulin G | 1 | 2016 | 806 | 0.100 |
Why?
|
| Transplantation, Autologous | 2 | 2016 | 286 | 0.100 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 3990 | 0.090 |
Why?
|
| Age Factors | 1 | 2019 | 2912 | 0.090 |
Why?
|
| Incidence | 3 | 2021 | 3375 | 0.090 |
Why?
|
| Survival Rate | 2 | 2014 | 2186 | 0.090 |
Why?
|
| Registries | 1 | 2019 | 1579 | 0.090 |
Why?
|
| Blood Glucose | 2 | 2015 | 1121 | 0.090 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2020 | 845 | 0.090 |
Why?
|
| Chronic Disease | 2 | 2020 | 1233 | 0.090 |
Why?
|
| Immunocompromised Host | 1 | 2013 | 306 | 0.090 |
Why?
|
| Echocardiography, Stress | 1 | 2010 | 18 | 0.080 |
Why?
|
| Complement C4b | 1 | 2010 | 5 | 0.080 |
Why?
|
| Capillaries | 1 | 2010 | 71 | 0.080 |
Why?
|
| HLA Antigens | 3 | 2020 | 218 | 0.080 |
Why?
|
| Plasmapheresis | 1 | 2010 | 33 | 0.080 |
Why?
|
| COS Cells | 3 | 1999 | 268 | 0.080 |
Why?
|
| Comorbidity | 2 | 2014 | 1605 | 0.080 |
Why?
|
| Blood Pressure | 1 | 2015 | 1400 | 0.080 |
Why?
|
| Pancreas | 2 | 2020 | 222 | 0.070 |
Why?
|
| Liver Transplantation | 1 | 2017 | 1102 | 0.070 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 588 | 0.070 |
Why?
|
| Vascular Malformations | 1 | 2010 | 112 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2008 | 25 | 0.070 |
Why?
|
| Urogenital Abnormalities | 1 | 2010 | 164 | 0.070 |
Why?
|
| Rabbits | 2 | 1999 | 673 | 0.070 |
Why?
|
| Metabolic Syndrome | 1 | 2011 | 364 | 0.070 |
Why?
|
| Troponin T | 1 | 2009 | 295 | 0.070 |
Why?
|
| Peptide Fragments | 1 | 2010 | 800 | 0.060 |
Why?
|
| Transplantation Conditioning | 1 | 2008 | 304 | 0.060 |
Why?
|
| Histocompatibility Testing | 2 | 2020 | 110 | 0.060 |
Why?
|
| Prevalence | 2 | 2010 | 2658 | 0.060 |
Why?
|
| Obesity | 2 | 2022 | 2394 | 0.060 |
Why?
|
| Babesiosis | 1 | 2005 | 2 | 0.060 |
Why?
|
| Blood Donors | 1 | 2005 | 60 | 0.060 |
Why?
|
| Lyme Disease | 1 | 2005 | 37 | 0.060 |
Why?
|
| Head | 1 | 2005 | 115 | 0.050 |
Why?
|
| Amino Acid Sequence | 2 | 1999 | 2669 | 0.050 |
Why?
|
| Evidence-Based Medicine | 1 | 2007 | 662 | 0.050 |
Why?
|
| Molecular Sequence Data | 2 | 1999 | 3770 | 0.050 |
Why?
|
| Biofeedback, Psychology | 1 | 2022 | 38 | 0.050 |
Why?
|
| Pelvic Floor | 1 | 2022 | 39 | 0.050 |
Why?
|
| Social Networking | 1 | 2021 | 17 | 0.050 |
Why?
|
| Transplantation, Homologous | 2 | 2016 | 652 | 0.040 |
Why?
|
| Reoperation | 1 | 2024 | 851 | 0.040 |
Why?
|
| Umbilical Cord | 1 | 2021 | 59 | 0.040 |
Why?
|
| Travel | 1 | 2021 | 124 | 0.040 |
Why?
|
| Autoantibodies | 2 | 2016 | 456 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 1949 | 0.040 |
Why?
|
| ABO Blood-Group System | 1 | 2020 | 66 | 0.040 |
Why?
|
| International Cooperation | 1 | 2020 | 165 | 0.040 |
Why?
|
| Fibrosis | 1 | 2021 | 421 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 3087 | 0.040 |
Why?
|
| Social Support | 1 | 2021 | 387 | 0.040 |
Why?
|
| Neoplasms | 1 | 2014 | 2955 | 0.040 |
Why?
|
| Subcellular Fractions | 1 | 1999 | 90 | 0.040 |
Why?
|
| Hyperinsulinism | 1 | 1999 | 62 | 0.040 |
Why?
|
| Sulfonylurea Receptors | 1 | 1998 | 12 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 210 | 0.040 |
Why?
|
| Weight Loss | 1 | 2022 | 515 | 0.040 |
Why?
|
| Precipitin Tests | 1 | 1998 | 143 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 1999 | 422 | 0.030 |
Why?
|
| Mutagenesis | 1 | 1999 | 347 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2022 | 1440 | 0.030 |
Why?
|
| BK Virus | 1 | 2018 | 60 | 0.030 |
Why?
|
| Hypoglycemia | 1 | 1999 | 183 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 1 | 2020 | 612 | 0.030 |
Why?
|
| Adolescent | 3 | 2013 | 20535 | 0.030 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2000 | 261 | 0.030 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 1999 | 273 | 0.030 |
Why?
|
| Child | 2 | 2014 | 25761 | 0.030 |
Why?
|
| Antibodies | 1 | 1998 | 365 | 0.030 |
Why?
|
| Proteasome Inhibitors | 1 | 2016 | 61 | 0.030 |
Why?
|
| Kinetics | 1 | 1998 | 1129 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1999 | 760 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 1998 | 526 | 0.030 |
Why?
|
| Animals | 4 | 2021 | 34781 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2000 | 767 | 0.030 |
Why?
|
| Proteinuria | 1 | 2015 | 110 | 0.030 |
Why?
|
| Stem Cell Transplantation | 1 | 2016 | 249 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 1999 | 812 | 0.030 |
Why?
|
| Serum Albumin | 1 | 2014 | 116 | 0.030 |
Why?
|
| Spores, Fungal | 1 | 2013 | 14 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2020 | 1304 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2000 | 1015 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2009 | 958 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2013 | 149 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2014 | 334 | 0.020 |
Why?
|
| Mortality | 1 | 2014 | 263 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 1999 | 1610 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1499 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2015 | 672 | 0.020 |
Why?
|
| Cadaver | 1 | 2010 | 119 | 0.020 |
Why?
|
| Time Factors | 1 | 2020 | 6440 | 0.020 |
Why?
|
| United States | 1 | 2024 | 11648 | 0.020 |
Why?
|
| Survivors | 1 | 2010 | 354 | 0.020 |
Why?
|
| Sinus of Valsalva | 1 | 2007 | 35 | 0.020 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2007 | 42 | 0.020 |
Why?
|
| Acute Disease | 1 | 2010 | 1160 | 0.020 |
Why?
|
| Calcium | 2 | 1999 | 1078 | 0.010 |
Why?
|
| Pulmonary Artery | 1 | 2007 | 456 | 0.010 |
Why?
|
| Glycosyltransferases | 1 | 1999 | 27 | 0.010 |
Why?
|
| Pinacidil | 1 | 1998 | 1 | 0.010 |
Why?
|
| Postprandial Period | 1 | 1999 | 90 | 0.010 |
Why?
|
| C-Peptide | 1 | 1999 | 109 | 0.010 |
Why?
|
| Guinea Pigs | 1 | 1998 | 161 | 0.010 |
Why?
|
| Cell Hypoxia | 1 | 1998 | 100 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 1999 | 212 | 0.010 |
Why?
|
| Islets of Langerhans | 1 | 1999 | 163 | 0.010 |
Why?
|
| Pancreatectomy | 1 | 1999 | 149 | 0.010 |
Why?
|
| Cardiovascular Agents | 1 | 1998 | 87 | 0.010 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 1998 | 129 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2000 | 1361 | 0.010 |
Why?
|
| Transfection | 1 | 1998 | 996 | 0.010 |
Why?
|
| Syndrome | 1 | 1999 | 1174 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1998 | 1347 | 0.010 |
Why?
|
| Ultrasonography | 1 | 1999 | 986 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 1998 | 803 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1998 | 3037 | 0.010 |
Why?
|
| Mutation | 1 | 1999 | 6226 | 0.000 |
Why?
|